Abstract Recent developments in biotechnological techniques such as protein purification and recombinant DNA technology have led to the production of many commercial protein- and peptide-based drugs. Although the intravenous route is the preferred mode of protein drug delivery, it is associated with pain, cost, and sterility concerns. These complications can be avoided with minimally invasive microneedle (MN)-mediated transdermal drug delivery to provide better patient compliance. Currently, various formulation and microfabrication techniques are being developed to facilitate MN-mediated protein drug delivery. The design of MNs primarily relies on the heterogeneous and viscoelastic property of the skin. Presently, several MN brands have been successfully marketed and others are actively undergoing clinical trials to confirm their efficacy in the delivery of drug candidates. This chapter mainly highlights the latest developments and limitations in MN-mediated protein and peptide drug delivery. The proposed mechanism of entry of drugs administered via MN into blood circulation also has been discussed.
Recent Advances and Challenges in Microneedle-Mediated Transdermal Protein and Peptide Drug Delivery
Rubhan Chandran,E. Tohit,J. Stanslas,T. Mahmood
Published 2019 in Biomaterials and Bionanotechnology
ABSTRACT
PUBLICATION RECORD
- Publication year
2019
- Venue
Biomaterials and Bionanotechnology
- Publication date
Unknown publication date
- Fields of study
Medicine, Engineering
- Identifiers
- External record
- Source metadata
Semantic Scholar
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
CITED BY
Showing 1-8 of 8 citing papers · Page 1 of 1